Risk of infection in patients with hidradenitis suppurativa on biologics or other immunomodulators: a systematic review and meta‐analysis

Abstract

AbstractHidradenitis suppurativa (HS) is a painful skin condition that significantly affects patients’ quality of life. Biologic agents, including anti‐TNF agents and IL‐17 inhibitors, have shown promise as treatment options for HS. However, there is concern about the increased risk of infections associated with these therapies. We conducted a systematic review and meta‐analysis following PRISMA and MOOSE guidelines. We searched PubMed and Embase until February 1, 2023. The primary outcome of interest was the incidence of any infectious complications. Secondary outcomes included serious and opportunistic infections in HS patients treated with biologics or other immunomodulators. Twenty‐four studies met our inclusion criteria, comprising 1,696 patients. The pooled incidence rate for any infection was 24.2%, primarily consisting of mild respiratory and skin infections. Subgroup analysis based on the mechanism of action (MOA) showed a pooled incidence of 7.77% for anti‐IL1, 14.24% for anti‐PDE4, and 21.96% for anti‐TNF. Notably, patients receiving anti‐IL17 had the highest incidence rate of infection at 33.6%, but the relative risk compared to placebo was not significantly elevated (0.99, 95% CI: 0.86–1.14). Serious infections were rare, with pooled incidences of 0.39% for anti‐IL17 and 0.03% for anti‐TNF. Opportunistic infections were infrequent, with 10 reported cases, including eight oral candidiasis, one cryptosporidiosis, and one Blastocystis hominis infection. The use of biologic therapies in HS patients does not significantly increase the risk of infectious complications. Additionally, the occurrence of serious or opportunistic infections in HS patients treated with biologics appears to be minimal.